J.‐P. Bronowicki

<scp>GIDEON</scp> (Global Investigation of therapeutic <scp>DE</scp> cisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis

Riccardo Lencioni, Masatoshi Kudo, Sheng‐Long Ye et al. · International Journal of Clinical Practice · 2013 · 222 citations

Medicine, Oncology, Pharmacotherapy +17

101 SVR4 AND SVR12 WITH AN INTERFERON-FREE REGIMEN OF BI201335 AND BI207127, +/- RIBAVIRIN, IN TREATMENT-NAIVE PATIENTS WITH CHRONIC GENOTYPE-1 HCV INFECTION: INTERIM RESULTS OF SOUND-C2

Stefan Zeuzem, Vincent Soriano, Tarik Asselah et al. · Journal of Hepatology · 2012 · 66 citations

Pharmacy, Infectious Diseases, Hepatitis Pharmacotherapy +13

50 ACTIVITY OF TELAPREVIR ALONE OR IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 2 AND 3 HEPATITIS-C PATIENTS: INTERIM RESULTS OF STUDY C209

Graham R. Foster, Christophe Hézode, J.‐P. Bronowicki et al. · Journal of Hepatology · 2009 · 53 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +16

58 TREATMENT OF CHRONIC HEPATITIS C WITH TELAPREVIR (TVR) IN COMBINATION WITH PEGINTERFERON-ALFA-2A WITH OR WITHOUT RIBAVIRIN: FURTHER INTERIM ANALYSIS RESULTS OF THE PROVE2 STUDY

G Dusheiko, Christophe Hézode, Stanislas Pol et al. · Journal of Hepatology · 2008 · 47 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +14

1094 100% SVR IN IL28B CC PATIENTS TREATED WITH 12 WEEKS OF TELAPREVIR, PEGINTERFERON AND RIBAVIRIN IN THE PROVE2 TRIAL

J.‐P. Bronowicki, Christophe Hézode, Leif Bengtsson et al. · Journal of Hepatology · 2012 · 46 citations

Pharmacy, Immunology, Pharmacotherapy +12